Emyria (ASX:EMD) Research & Development: A$0.41 Mil (TTM As of Dec. 2025)


What is Emyria Research & Development?

Emyria ASX:EMD -2.56% Research & Development is A$0.41 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Emyria's Research & Development for the six months ended in Dec. 2025 was A$0.24 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.41 Mil.

Emyria  (ASX:EMD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Emyria Research & Development Related Terms

Emyria Research & Development Historical Data

* Premium members only.

The historical data trend for Emyria's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Research & Development Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 2.62 2.21 1.80 2.09 0.61

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.00 0.44 0.18 0.24

Emyria Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.41 Mil mean?
Emyria (ASX:EMD) has a Research & Development of A$0.41 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Emyria and its competitors.
Is Emyria's Research & Development too high?
Emyria's current Research & Development is A$0.41 Mil.
How does Emyria's Research & Development compare to VEEV and BTSG?
Emyria's Research & Development of A$0.41 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Emyria and its competitors. Emyria's current Research & Development is A$0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 26.7% above its estimated fair value. The current Research & Development is A$0.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Research & Development is A$0.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.